Progyny, Inc. (NASDAQ:PGNY - Get Free Report) Chairman David J. Schlanger purchased 150,000 shares of the business's stock in a transaction that occurred on Thursday, December 26th. The shares were purchased at an average price of $14.68 per share, for a total transaction of $2,202,000.00. Following the completion of the acquisition, the chairman now owns 228,269 shares of the company's stock, valued at $3,350,988.92. The trade was a 191.65 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
NASDAQ PGNY traded up $0.18 during trading hours on Thursday, hitting $14.71. The company had a trading volume of 1,918,778 shares, compared to its average volume of 1,423,054. The firm has a 50 day simple moving average of $15.27 and a 200 day simple moving average of $20.63. The firm has a market capitalization of $1.25 billion, a price-to-earnings ratio of 25.36, a PEG ratio of 1.64 and a beta of 1.35. Progyny, Inc. has a 52 week low of $13.39 and a 52 week high of $42.08.
Progyny (NASDAQ:PGNY - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $0.11 EPS for the quarter, missing analysts' consensus estimates of $0.37 by ($0.26). The company had revenue of $286.63 million during the quarter, compared to the consensus estimate of $296.85 million. Progyny had a return on equity of 11.36% and a net margin of 5.03%. Progyny's quarterly revenue was up 2.0% on a year-over-year basis. During the same period in the previous year, the company earned $0.16 EPS. On average, research analysts forecast that Progyny, Inc. will post 0.59 earnings per share for the current year.
Several equities research analysts have recently issued reports on the company. Leerink Partners decreased their target price on Progyny from $25.00 to $21.00 and set a "market perform" rating for the company in a research report on Thursday, September 19th. Truist Financial restated a "hold" rating and set a $19.00 price target (down previously from $26.00) on shares of Progyny in a research report on Wednesday, November 13th. Bank of America dropped their target price on shares of Progyny from $22.00 to $21.00 and set a "buy" rating on the stock in a research note on Wednesday, November 13th. JPMorgan Chase & Co. restated a "neutral" rating and set a $17.00 price target (down previously from $22.00) on shares of Progyny in a research note on Monday, December 2nd. Finally, JMP Securities downgraded Progyny from an "outperform" rating to a "market perform" rating in a research note on Thursday, September 19th. Nine investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, Progyny currently has an average rating of "Hold" and a consensus price target of $25.00.
Get Our Latest Analysis on Progyny
Several hedge funds and other institutional investors have recently modified their holdings of PGNY. Franklin Resources Inc. lifted its holdings in Progyny by 17.0% in the third quarter. Franklin Resources Inc. now owns 48,248 shares of the company's stock worth $759,000 after buying an additional 7,003 shares during the period. Tidal Investments LLC raised its position in shares of Progyny by 67.7% in the 3rd quarter. Tidal Investments LLC now owns 60,722 shares of the company's stock worth $1,018,000 after acquiring an additional 24,507 shares in the last quarter. Disciplined Growth Investors Inc. MN boosted its position in shares of Progyny by 56.5% during the third quarter. Disciplined Growth Investors Inc. MN now owns 826,726 shares of the company's stock valued at $13,856,000 after purchasing an additional 298,314 shares in the last quarter. Barclays PLC grew its stake in Progyny by 530.4% in the third quarter. Barclays PLC now owns 706,157 shares of the company's stock worth $11,835,000 after purchasing an additional 594,140 shares during the period. Finally, Y Intercept Hong Kong Ltd bought a new position in Progyny in the third quarter worth $469,000. 94.93% of the stock is owned by institutional investors.
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Progyny, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Progyny wasn't on the list.
While Progyny currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.